LYT-200

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
90 patients (estimated)
Sponsors
PureTech Health
Tags
Monoclonal Antibody, Galectin-9 Protein
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1636
NCT Identifier
NCT05829226

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.